Indonesia approves first local COVID vaccine for emergency use - media

Indonesia approves first local COVID vaccine for emergency use – media

JAKARTA, Sept 28 (Reuters) – Indonesia has approved its first locally produced COVID-19 vaccine for emergency use for people over 18, the head of the national food agency said on Wednesday. and medicines (BPOM) quoted by the media.

The Indovac vaccine was developed by Indonesia’s state-owned pharmaceutical company Bio Farma and Baylor College of Medicine in Houston, Texas.

Penny Lukito, the head of BPOM, was quoted by news portal CNN Indonesia as saying the approval was “given as a primary vaccine for adults”.

Join now for FREE unlimited access to Reuters.com

Penny and a Bio Farma spokesperson did not immediately respond to requests for comment.

Bio Farma said this month that it would produce 20 million doses of the vaccine in 2022 and 100 million doses by 2024. It also said it had applied for a halal certificate – which would make the vaccine Islamic – with the competent authorities.

Indonesia is the largest Muslim-majority country in the world.

Bio Farma chief Honesti Basyir said earlier this month that the vaccines were meant to “help reduce the country’s dependence on imported vaccines”, adding that 80% of Indovac is locally sourced.

Indonesia, which last year reported one of the highest COVID-19 transmission rates in the world, used vaccines produced by Chinese companies Sinovac Biotech (SVA.O), Pfizer Inc and BioNTech ( 22UAy.DE) as well as Moderna Inc (MRNA.O).

Bio Farma said it has also sought emergency use approval from the World Health Organization (WHO).

Indonesia is also developing another local vaccine called Inavac.

Join now for FREE unlimited access to Reuters.com

Reporting by Stanley Widianto; Editing by Raju Gopalakrishnan

Our standards: The Thomson Reuters Trust Principles.

Leave a Comment

Your email address will not be published.